Heuron Collaborating with National University Hospital in Singapore

2024-05-16

Heuron Solution Utilized for Analysis of Data from Approximately 700 Subjects

Involvement of World-Renowned Researcher, Associate Professor Christopher Chen




Heuron, a medical artificial intelligence (AI) company specializing in neurological disorders, formed a research collaboration with National University Hospital (NUH) on March 27th 2024. Both parties initiated a retrospective research project on disease progression across the Alzheimer’s Disease (AD) continuum based on brain imaging analysis using artificial intelligence.

On the 8th of April 2024, Heuron visited NUH and installed their Alzheimer's analysis solutions, Heuron AD and Heuron Brain PET for use by researchers at NUH.


The research will utilize approximately 700 brain MRI images and over 230 brain PET images, from an ongoing longitudinal study. These images were collected from individuals with no cognitive impairment, mild cognitive impairment or dementia at baseline, 2 years and between 4 and 5 years after baseline. Heuron's solutions will be validated for their accuracy in analyzing cross-sectional and longitudinal measures of cognition for the differentiation between patient groups, thereby demonstrating their potential for early diagnosis of AD.


The research will be led by Associate Professor Christopher Chen, a world-renowned researcher in dementia and Visiting Consultant, Department of Psychological Medicine, NUH, with Dr Ngam Pei Ing, Consultant, Division of Neuroimaging, Department of Diagnostic Imaging, NUH, as a key collaborator. A/Prof Chen is also Director of the Memory, Ageing and Cognition Centre at the National University Health System and Associate Professor at the Department of Pharmacology in the National University of Singapore Yong Loo Lin School of Medicine.


The study is expected to continue for about a year, with results to be formally announced through publication in academic journals.


Dr. Shin Dong-hoon, CEO of Heuron, expressed pleasure in the collaborative utilisation of the high-quality data from NUH for this research. He hoped that this research would thoroughly validate the effectiveness of Heuron AD and Heuron Brain PET and open up possibilities for clinical application.